Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated

Marc L Hyer1, Sunil Sudarshan, David A Schwartz

  • 1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.

Cancer Gene Therapy
|April 8, 2003
PubMed

Insights

Fas Ligand (FasL) gene therapy using adenovirus effectively triggers prostate cancer cell death. Infected cells release debris that kills neighboring cancer cells via FasL-mediated bystander killing, supporting FasL development.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Prostate cancer (PCa) gene therapy faces delivery challenges.
  • Fas-mediated apoptosis is a potential therapeutic strategy for PCa.
  • Previous studies showed adenovirus expressing FasL (AdGFPFasL(TET)) induces apoptosis in PCa cells.

Purpose of the Study:

  • To investigate the bystander killing effect of AdGFPFasL(TET)-infected PCa cells.
  • To determine if apoptotic bodies and cellular debris from infected cells can induce cell death in neighboring cells.
  • To elucidate the mechanism of this bystander killing.

Main Methods:

  • Infection of PCa cell lines with AdGFPFasL(TET).
  • Light microscopy to observe apoptotic bodies and cellular debris.
  • Co-incubation assays with target cells (Jurkat, PPC-1, PC-3, DU145, K-562).
  • Treatment with caspase inhibitor (Z-VAD-FMK) and Fas neutralizing antibody (ZB-4) to assess mechanism.

Main Results:

  • AdGFPFasL(TET)-infected cells release apoptotic bodies and debris.
  • This material induced FasL-mediated bystander killing in Jurkat, PPC-1, and PC-3 cells.
  • Bystander killing was inhibited by caspase inhibitor and Fas antibody, confirming Fas/FasL interaction.
  • Near-complete killing of target cells observed at a 1:1 effector to target ratio.

Conclusions:

  • Prostate cancer cells infected with AdGFPFasL(TET) release debris that mediates bystander killing.
  • This bystander effect is Fas/FasL dependent.
  • FasL holds promise as a gene therapy agent for prostate cancer due to its bystander killing capability.

Related Concept Videos